Autopsy report · NCT04777708

BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer

“Withdrawn by sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months before it started.
• Ran for about 1 year 5 months before it stopped.
• 1 participant enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Early Phase 1

Sponsor

Jonsson Comprehensive Cancer Center

Sponsor type

University, hospital or other

Conditions

Advanced Hepatocellular Carcinoma; BCLC Stage B Hepatocellular Carcinoma; BCLC Stage C Hepatocellular Carcinoma; Refractory Hepatocellular Carcinoma

Interventions

Nanoplexed Poly I:C BO-112; Pembrolizumab

Participants

1

Sites

1

Countries

United States

Trials that died the same way

• An Exploratory Investigation to Assess Changes in Quality of Life for Individuals With Type 2 Diabetes After Taking a Meal-replacement Shake.
  “Sponsor withdrawn” (97% match in meaning)
• Study of Atiprimod Treatment for Patients With Advanced Cancer
  “Sponsor Withdrew” (94% match in meaning)
• Vasculaire Leg Compression Device for the Treatment of Restless Legs Syndrome - A Prospective Clinical Study
  “sponsor withdrew support” (89% match in meaning)
• Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism
  “Withdrawal of sponsorship” (88% match in meaning)
• Silymarin in NAFLD
  “Sponsor withdrawn their agreement” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.